Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

121. Is the Risk of Bleeding Among Older Adults With Atrial Fibrillation Lower With Antiplatelet Compared With Oral Anticoagulants?

Is the Risk of Bleeding Among Older Adults With Atrial Fibrillation Lower With Antiplatelet Compared With Oral Anticoagulants? TAKE-HOME MESSAGE Older adults have a lower risk of any severity of bleeding (includes both major and minor bleeding) when treated with aspirin or clopidogrel compared to warfarin. However, if minor bleeding is excluded, only the subgroup of patients aged 80 years or older demonstrate a lower risk the of major bleeding with antiplatelet agents. Is the Risk of Bleeding (...) Among Older Adults With Atrial Fibrillation Lower With Antiplatelet Compared With Oral Anticoagulants? EBEM Commentators Cameron Gettel, MD Elizabeth M. Goldberg, MD, ScM Department of Emergency Medicine Alpert Medical School of Brown University Providence, RI Results Commentary Several systematic reviews have previously shown that the risk of bleeding with long-term treatment with aspirin was lower than with warfarin. 2,3 It is common clinical practice to use antiplatelet agents as alternatives

2018 Annals of Emergency Medicine Systematic Review Snapshots

122. Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. (PubMed)

Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. The comparative safety and effectiveness of treatments to prevent thromboembolic complications in atrial fibrillation (AF) remain uncertain.To compare the effectiveness of medical and procedural therapies in preventing thromboembolic events and bleeding complications in adults with nonvalvular AF.English-language studies in several databases from 1 January 2000 to 14 February 2018.Two

2018 Annals of Internal Medicine

123. Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrial fibrillation?

Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrial fibrillation? Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrial fibrillation? - CanadiEM Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrial fibrillation? In , by Kerstin de Wit October 23, 2018 All the content from the Blood & Clots series can be found . CanMEDS Roles addressed : Expert, health advocate, communicator Case (...) Description A 52 year old lady attends the emergency department with a several week history of palpitations. She is found to have atrial fibrillation. You have started a beta blocker and she is in a stable condition for discharge. You evaluate the need for stroke prevention and discuss the options with her. Main Text A 52 year old lady attends the emergency department with previously unrecognized atrial fibrillation. She has had intermittent palpitations for a month or so and her first ECG showed atrial

Full Text available with Trip Pro

2018 CandiEM

124. Chronic atrial fibrillation

Chronic atrial fibrillation Chronic atrial fibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Chronic atrial fibrillation Last reviewed: February 2019 Last updated: October 2018 Summary Chaotic and irregular atrial arrhythmia, the prevalence of which increases progressively with age. Patients frequently have co-existing cardiac or non-cardiac conditions, such as hypertension, coronary artery disease (...) , pacemakers, and ablation of the atrioventricular node need to be weighed based on multiple clinical factors to optimise patient outcome. Definition Atrial fibrillation (AF) is a supraventricular tachyarrhythmia. It is characterised by uncoordinated atrial activity on the surface ECG, with fibrillatory waves of varying shapes, amplitudes, and timing associated with an irregularly irregular ventricular response when atrioventricular (AV) conduction is intact. [Figure caption and citation for the preceding

2018 BMJ Best Practice

125. Newer technologies for detection of atrial fibrillation. (PubMed)

Newer technologies for detection of atrial fibrillation. Atrial fibrillation is a common arrhythmia that is associated with increased risk of stroke, which can be reduced with appropriate anticoagulation treatment. However, it remains underdiagnosed in contemporary clinical practice using conventional detection methods, resulting in missed opportunities to implement appropriate treatment. Newer technologies developed in recent years can potentially enhance the detection of atrial fibrillation (...) and overcome certain limitations of the conventional methods. However, uncertainties remain about their use and the significance of atrial fibrillation detected by some of these newer technologies. This review examines the evidence supporting the use of some of these technologies and evaluates their applications in certain clinical scenarios.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights

2018 BMJ

126. Meta-Analysis Comparing Dual Versus Single Antiplatelet Therapy in Combination With Antithrombotic Therapy in Patients With Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention With Stent Implantation

Meta-Analysis Comparing Dual Versus Single Antiplatelet Therapy in Combination With Antithrombotic Therapy in Patients With Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention With Stent Implantation The coexistence of atrial fibrillation and coronary artery disease is commonly found in clinical practice. The aim of this meta-analysis is to compare the clinical efficacy and safety of dual versus single antiplatelet therapy in combination with antithrombotic therapy in patients (...) with atrial fibrillation undergoing percutaneous coronary intervention. PubMed, EMBASE and Web of Science databases were systematically evaluated for articles published up to October 31, 2017. The risk ratios (RR) were extracted from each study. Pooled estimates with corresponding 95% confidence intervals (CI) were estimated by a fixed or random-effects model. Eight studies involving a total of 10,861 patients with atrial fibrillation were included in this meta-analysis. Five thousand sixty-six

Full Text available with Trip Pro

2018 EvidenceUpdates

127. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS

A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS We tested the hypothesis that atrioventricular (AV) junction ablation in conjunction biventricular pacing [cardiac resynchronization (CRT)] pacing is superior to pharmacological rate-control therapy in reducing heart failure (HF) and hospitalization in patients with permanent atrial fibrillation (AF) and narrow QRS.We randomly

Full Text available with Trip Pro

2018 EvidenceUpdates

128. Using the MB-LATER score for predicting arrhythmia outcome after catheter ablation for atrial fibrillation: The Guangzhou atrial fibrillation project

Using the MB-LATER score for predicting arrhythmia outcome after catheter ablation for atrial fibrillation: The Guangzhou atrial fibrillation project Several clinical scoring systems have been derived to predict the arrhythmia outcome of catheter ablation (CA) for atrial fibrillation (AF) but which is better is not clear. Simple clinical risk scores (that any clinician can use in the everyday clinic) can help assess the likelihood of recurrence of AF following CA and the simple MB-LATER score

2018 EvidenceUpdates

129. Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation. (PubMed)

Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation. Stroke rates in patients with nonvalvular atrial fibrillation (AF) who are not receiving anticoagulant therapy vary widely across published studies; the resulting effect on the net clinical benefit of anticoagulation in AF is unknown.To determine the effect of variation in published AF stroke rates on the net clinical benefit of anticoagulation.Markov model decision analysis (...) and Risk Factors In Atrial Fibrillation) study and greatest using those from the Danish National Patient Registry (6290 QALYs [95% CI, ±2.3%] vs. 24 110 QALYs [CI, ±1.9%]; P < 0.001). The optimal CHA2DS2-VASc score threshold for anticoagulation was 3 or more using stroke rates from ATRIA, 2 or more using those from the Swedish AF cohort study, 1 or more using those from the SPORTIF (Stroke Prevention using ORal Thrombin Inhibitor in atrial Fibrillation) study, and 0 or more using those from the Danish

2018 Annals of Internal Medicine

130. Atrial Fibrillation: Screening With Electrocardiography

Atrial Fibrillation: Screening With Electrocardiography Final Update Summary: Atrial Fibrillation: Screening With Electrocardiography - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Atrial Fibrillation: Screening With Electrocardiography Release Date: August 2018 Recommendation Summary Population Recommendation Grade Adults The USPSTF concludes that the current evidence is insufficient (...) to assess the balance of benefits and harms of screening for atrial fibrillation with electrocardiography (ECG). See the for suggestions for practice regarding the I statement. To read the recommendation statement in JAMA , select . To read the evidence summary in JAMA , select . ( ) Related Information for Consumers Related Information for Health Professionals Supporting Documents ( ) ( ) Clinical Summary Clinical summaries are one-page documents that provide guidance to primary care clinicians

2018 U.S. Preventive Services Task Force

131. Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation

Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation Evidence suggests an excess risk of non-thromboembolic major adverse cardiac events (MACE) associated with atrial fibrillation (AF), particularly in individuals free of overt coronary artery disease (CAD). Metabolic syndrome (MetS) increases cardiovascular risk in the general population, but less is known how it influences outcomes in AF patients. We aimed to assess whether

Full Text available with Trip Pro

2018 EvidenceUpdates

132. Screening for Atrial Fibrillation With Electrocardiography: US Preventive Services Task Force Recommendation Statement. (PubMed)

Screening for Atrial Fibrillation With Electrocardiography: US Preventive Services Task Force Recommendation Statement. Atrial fibrillation is the most common type of cardiac arrhythmia (irregular heartbeat), and its prevalence increases with age, affecting about 3% of men and 2% of women aged 65 to 69 years and about 10% of adults 85 years and older. Atrial fibrillation is a major risk factor for ischemic stroke, increasing risk of stroke by as much as 5-fold. Approximately 20% of patients who (...) have a stroke associated with atrial fibrillation are first diagnosed with atrial fibrillation at the time of stroke or shortly thereafter.To issue a new US Preventive Services Task Force (USPSTF) recommendation on screening for atrial fibrillation with electrocardiography (ECG).The USPSTF reviewed the evidence on the benefits and harms of screening for atrial fibrillation with ECG in adults 65 years and older, the effectiveness of screening with ECG for detecting previously undiagnosed atrial

Full Text available with Trip Pro

2018 JAMA

133. Screening for Atrial Fibrillation With Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Screening for Atrial Fibrillation With Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force. Atrial fibrillation is the most common arrhythmia and increases the risk of stroke.To review the evidence on screening for nonvalvular atrial fibrillation with electrocardiography (ECG) and stroke prevention treatment in asymptomatic adults 65 years or older to inform the US Preventive Services Task Force.MEDLINE, Cochrane Library, and trial registries (...) through May 2017; references; experts; literature surveillance through June 6, 2018.English-language randomized clinical trials (RCTs), prospective cohort studies evaluating detection rates of atrial fibrillation or harms of screening, and systematic reviews evaluating stroke prevention treatment. Eligible treatment studies compared warfarin, aspirin, or novel oral anticoagulants (NOACs) with placebo or no treatment. Studies were excluded that focused on persons with a history of cardiovascular

Full Text available with Trip Pro

2018 JAMA

134. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. (PubMed)

Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. We compared clinical outcomes in patients with AF with and without diabetes in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.The main efficacy endpoints were SSE and mortality; safety endpoints were major and major/clinically relevant non-major bleeding. A total of 4547/18 201 (24.9%) patients had diabetes who were

Full Text available with Trip Pro

2018 European heart journal. Cardiovascular pharmacotherapy

135. Source Determination in Atrial Fibrillation (PubMed)

Source Determination in Atrial Fibrillation Techniques to ablate persistent atrial fibrillation (AF) continue to evolve. Recent technological and strategic innovations have included a focus on mapping and ablating AF sources. These attempts have not yet yielded a consistent improvement in clinical outcomes following AF ablation. Advancements in these techniques in the next few years, however, may enhance our ability to map and ablate AF as well as further our understanding of the mechanisms

Full Text available with Trip Pro

2018 Arrhythmia & electrophysiology review

136. The Impact of Advances in Atrial Fibrillation Ablation Devices on the Incidence and Prevention of Complications (PubMed)

The Impact of Advances in Atrial Fibrillation Ablation Devices on the Incidence and Prevention of Complications The number of patients with atrial fibrillation currently referred for catheter ablation is increasing. However, the number of trained operators and the capacity of many electrophysiology labs are limited. Accordingly, a steeper learning curve and technical advances for efficient and safe ablation are desirable. During the last decades several catheter-based ablation devices have been

Full Text available with Trip Pro

2018 Arrhythmia & electrophysiology review

137. Usefulness of the Addition of Renal Function to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Atrial Fibrillation

Usefulness of the Addition of Renal Function to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without Atrial Fibrillation Research is conflicting whether kidney function should be incorporated in thromboembolism risk prediction. Our published data showed that the CHA2DS2-VASc score predicts thromboembolism and mortality in those without atrial fibrillation. We used the Rochester Epidemiology Project medical records system to retrospectively evaluate whether (...) adding renal impairment (1 point) to the CHA2DS2-VASc score (-R) enhances the score's prediction of mortality, thromboembolism, and atrial fibrillation in patients without atrial fibrillation. We identified patients that had an implantable cardiac monitoring device placed from January 1, 2004 to December 31, 2013, which was defined as the start date. Follow-up was through March 7, 2016. An implantable device was required to discern the absence of atrial fibrillation. Renal impairment was defined

2018 EvidenceUpdates

138. Should Patients Undergo Atrial Fibrillation Screening for Primary Stroke Prevention?

Should Patients Undergo Atrial Fibrillation Screening for Primary Stroke Prevention? Should Patients Undergo Atrial Fibrillation Screening for Primary Stroke Prevention? – Clinical Correlations Search Should Patients Undergo Atrial Fibrillation Screening for Primary Stroke Prevention? July 26, 2018 7 min read By Dixon Yang, MD Peer Reviewed Abstract Atrial fibrillation (AF) is a common arrhythmia, especially in the elderly, and is often asymptomatic. However, absence of symptoms does not confer (...) be interpreted with caution. While a significant portion of patients with screen-detected AF may qualify for anticoagulation, it is unclear which patients would benefit with improved vascular outcomes. Introduction Atrial fibrillation (AF) is a sustained arrhythmia commonly encountered in clinical practice, especially in those over age 65. [1,2]. However, absence of symptoms does not confer a better prognosis and is [3]. Up to 5% of patients with AF present with ischemic stroke as their first manifestation

2018 Clinical Correlations

139. Atrial fibrillation

Atrial fibrillation Top results for atrial fibrillation - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look (...) like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for atrial fibrillation The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials

2018 Trip Latest and Greatest

140. Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial. (PubMed)

Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial. Opportunistic screening for atrial fibrillation (AF) is recommended, and improved methods of early identification could allow for the initiation of appropriate therapies to prevent the adverse health outcomes associated with AF.To determine the effect of a self-applied wearable electrocardiogram (ECG) patch in detecting AF and the clinical

2018 JAMA